← Back to Search


BMS-986449 + Nivolumab for Advanced Cancer

Phase 1 & 2
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 4 years
Awards & highlights

Study Summary

This trial tests a new cancer drug to see if it's safe and effective for treating advanced solid tumors.

Who is the study for?
This trial is for adults with advanced solid tumors that can't be surgically removed or have spread (metastatic), and who haven't responded to, can't receive, or had adverse reactions to standard treatments. Part of the study focuses on those with specific cancers like non-small cell lung cancer and triple-negative breast cancer.Check my eligibility
What is being tested?
The study is testing BMS-986449 both alone and combined with Nivolumab to see how safe they are and if they work in treating various advanced solid tumors. Participants will be given these drugs to assess their effectiveness against the tumors.See study design
What are the potential side effects?
While not specified here, common side effects for drugs like BMS-986449 and Nivolumab may include fatigue, nausea, skin reactions at the injection site, immune-related issues such as inflammation in organs, potential infections due to lowered immunity.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of deaths
Number of participants with AEs leading to discontinuation
Number of participants with Adverse Events (AEs)
+2 more
Secondary outcome measures
Area under the concentration-time curve within a dosing interval (AUC[TAU])
Maximum observed plasma concentration (Cmax)
Time of maximum observed concentration within a dosing interval (Tmax)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohortsExperimental Treatment1 Intervention
Group II: Dose Escalation: BMS-986449 monotherapyExperimental Treatment1 Intervention
Group III: Dose Escalation: BMS-986449 + nivolumabExperimental Treatment2 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,639 Previous Clinical Trials
4,128,900 Total Patients Enrolled

Media Library

BMS-986449 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05888831 — Phase 1 & 2
Solid Tumors Research Study Groups: Dose Escalation: BMS-986449 monotherapy, Dose Escalation: BMS-986449 + nivolumab, Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts
Solid Tumors Clinical Trial 2023: BMS-986449 Highlights & Side Effects. Trial Name: NCT05888831 — Phase 1 & 2
BMS-986449 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05888831 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare centers are administering this clinical experiment in the city?

"This trial includes patients from the R.J. Zuckerberg Cancer Center in Lake Success, Local Institution - 0016 based in Brussels, and Local Institution - 0017 found in Gent, as well as 20 other sites across the globe."

Answered by AI

Is there still capacity for participants in this medical experiment?

"Data available on clinicaltrials.gov suggests that this particular medical trial is not presently seeking participants; the study was posted initially June 1st 2023 and last updated May 25th of the same year. Nevertheless, there are 2646 other studies actively recruiting candidates right now."

Answered by AI
~57 spots leftby May 2025